Literature DB >> 31285230

EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates.

Maiken Cavling Arendrup1,2,3, Karin Meinike Jørgensen4, Rasmus Krøger Hare4, Manuel Cuenca-Estrella5, Oscar Zaragoza5.   

Abstract

Rezafungin is a new long-acting echinocandin currently in phase 3 development. Epidemiological cutoff values are necessary for breakpoint setting but have not been established due to unexplained interlaboratory MIC variations observed in a prior multicenter study. Here we investigated if the choice of microtiter plates affected the variability when anidulafungin was included as a comparator. Testing by the EUCAST E.Def 7.3.1 reference method using tissue and cell culture-treated polystyrene plates (TC plates) and untreated polystyrene plates (UT plates) from four manufacturers was performed. Six control strains (Candida albicans, n = 3; C. krusei, n = 2; C. parapsilosis, n = 1) were tested (520 MICs). Subsequently, 5 or 6 wild-type isolates and 4 or 5 fks mutants of C. albicans, C. glabrata, C. krusei, C. parapsilosis (wild type only), and C. tropicalis were tested (930 MICs). For each strain-plate combination, ≥98% of the repetitive MICs were within 3 dilutions. The rezafungin modal MICs for the collated C. albicans control strain distributions were 0.016 mg/liter across TC plates but 0.03 mg/liter across UT plates, whereas they were 0.004 mg/liter and 0.016 mg/liter, respectively, for anidulafungin. The difference was most pronounced with Falcon plates and was not observed for C. krusei and C. parapsilosis Eleven rezafungin MICs for mutants overlapped with the MICs for wild-type isolates (TC plates, n = 4; UT plates, n = 7). For anidulafungin, five overlaps (all UT plates) were observed. Most overlaps (rezafungin, n = 5; anidulafungin, n = 3) were caused by fks mutants of C. tropicalis (Fks1, F650F/L) and C. glabrata (Fks2. D666Y; rezafungin, n = 2; anidulafungin, n = 1). Interlaboratory variation was low. The use of TC plates resulted in lower MICs, particularly for C. albicans and Falcon plates, ad this was more often the case for anidulafungin than for rezafungin. Adoption of TC plates for EUCAST antifungal susceptibility testing would improve interlaboratory reproducibility and the separation of non-wild-type and wild-type strains.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Candidazzm321990; antifungal susceptibility testing; broth microdilution; echinocandins

Mesh:

Substances:

Year:  2019        PMID: 31285230      PMCID: PMC6709479          DOI: 10.1128/AAC.00659-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.

Authors:  Rasmus Hare Jensen; Ulrik Stenz Justesen; Annika Rewes; David S Perlin; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

3.  Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis.

Authors:  Rasmus Hare Jensen; Helle Krogh Johansen; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

4.  Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method.

Authors:  M C Arendrup; J Meletiadis; O Zaragoza; K M Jørgensen; L J Marcos-Zambrano; L Kanioura; M Cuenca-Estrella; J W Mouton; J Guinea
Journal:  Clin Microbiol Infect       Date:  2018-03-02       Impact factor: 8.067

5.  Target enzyme mutations confer differential echinocandin susceptibilities in Candida kefyr.

Authors:  Janet F Staab; Dionysios Neofytos; Peter Rhee; Cristina Jiménez-Ortigosa; Sean X Zhang; David S Perlin; Kieren A Marr
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

6.  CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility.

Authors:  B Radha Krishnan; Kenneth D James; Karen Polowy; B J Bryant; Anu Vaidya; Steve Smith; Christopher P Laudeman
Journal:  J Antibiot (Tokyo)       Date:  2016-08-10       Impact factor: 2.649

7.  Effects of Treated versus Untreated Polystyrene on Caspofungin In Vitro Activity against Candida Species.

Authors:  Annette W Fothergill; Dora I McCarthy; Mohammad T Albataineh; Carmita Sanders; Maria McElmeel; Nathan P Wiederhold
Journal:  J Clin Microbiol       Date:  2016-01-13       Impact factor: 5.948

Review 8.  Echinocandin resistance: an emerging clinical problem?

Authors:  Maiken C Arendrup; David S Perlin
Journal:  Curr Opin Infect Dis       Date:  2014-12       Impact factor: 4.915

9.  Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.

Authors:  Elizabeth A Lakota; Justin C Bader; Voon Ong; Ken Bartizal; Lynn Miesel; David R Andes; Sujata M Bhavnani; Christopher M Rubino; Paul G Ambrose; Alexander J Lepak
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

10.  Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.

Authors:  Michael A Pfaller; Shawn A Messer; Paul R Rhomberg; Ronald N Jones; Mariana Castanheira
Journal:  J Antimicrob Chemother       Date:  2016-06-10       Impact factor: 5.790

View more
  6 in total

1.  Rezafungin In Vitro Activity against Contemporary Nordic Clinical Candida Isolates and Candida auris Determined by the EUCAST Reference Method.

Authors:  Marie Helleberg; Karin Meinike Jørgensen; Rasmus Krøger Hare; Raluca Datcu; Anuradha Chowdhary; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

2.  Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).

Authors:  Michael A Pfaller; Cecilia Carvalhaes; Shawn A Messer; Paul R Rhomberg; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 3.  Rezafungin-Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins.

Authors:  Guillermo Garcia-Effron
Journal:  J Fungi (Basel)       Date:  2020-11-01

4.  Azole-Resistant Aspergillus fumigatus Clinical Isolate Screening in Azole-Containing Agar Plates (EUCAST E.Def 10.1): Low Impact of Plastic Trays Used and Poor Performance in Cryptic Species.

Authors:  Julia Serrano-Lobo; Ana Gómez; Belén Rodríguez-Sánchez; Patricia Muñoz; Pilar Escribano; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

Review 5.  Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy.

Authors:  Derry K Mercer; Marcelo D T Torres; Searle S Duay; Emma Lovie; Laura Simpson; Maren von Köckritz-Blickwede; Cesar de la Fuente-Nunez; Deborah A O'Neil; Alfredo M Angeles-Boza
Journal:  Front Cell Infect Microbiol       Date:  2020-07-07       Impact factor: 5.293

Review 6.  Review on Current Status of Echinocandins Use.

Authors:  Martyna Mroczyńska; Anna Brillowska-Dąbrowska
Journal:  Antibiotics (Basel)       Date:  2020-05-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.